Neratinib: An Option for HER2-Positive Metastatic Breast Cancer

Joyce A. O’Shaughnessy, MD, Ruth O’Regan, MD, and Claudine Isaacs, MD

Abstract: Metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer is currently incurable. The primary goals of treatment are to prolong survival while optimizing quality of […]

Highlights in Myelodysplastic Syndromes From the 2020 American Society of Clinical Oncology Annual Meeting and the 25th European Hematology Association Congress

A Review of Selected Presentations From the 2020 ASCO Annual Meeting and the EHA25 Congress   Clinical Benefit of Luspatercept in Patients With Lower-Risk MDS and […]

Highlights in Chronic Lymphocytic Leukemia From the 2020 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2020 ASCO Meeting   Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND […]

Back to Archive